Morpholinylanthracyclines: Cytotoxicity and antitumor activity of differently modified derivatives

Investigational New Drugs

Volumn 14, Issue 2, 1996, Pages 139-146

  Ripamonti, Marina ^a,b   Capolongo, Laura ^a   Melegaro, Giulia ^a   Gornati, Carlo ^a   Bargiotti, Alberto ^a   Caruso, Michele ^a   Grandi, Maria ^a   Suarato, Antonino ^a  

^a Oncology Department   (Italy)

^b PFIZER INC   (United States)

Author keywords

Anthracyclines; Drug resistance; Morpholinylanthracyclines

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; MORPHOLINYLANTHRACYCLINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CHEMICAL MODIFICATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA P 388; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SURVIVAL TIME;

EID: 0029802281     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00210784     Document Type: Article

References (21)

1. Streeter DG, Taylor DL, Acton EM, Peters JH: Comparative cytotoxicities of various morpholinyl anthracyclines. Cancer Chemother Pharmacol 14:160-164, 1985
2. Streeter DG, Johl JS, Gordon GR, Peters JH: Uptake and retention of morpholinyl anthracyclines by adriamycinsensitive and -resistant P388 cells. Cancer Chemother Pharmacol 16:247-252, 1986
3. Watanabe M, Komeshima N, Nakajima S, Tsuruo T: MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells. Cancer Res 48:6653-6657, 1988
4. Watanabe M, Komeshima N, Naito M, Isoe T, Otake N, Tsuruo T: Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleitropic drug-resistant cells. Cancer Res 51:157-161, 1991
5. Grandi M, Pezzoni G, Ballinari D, Capolongo L, Suarato A, Bargiotti A, Faiardi D, Spreafico F: Novel anthracycline analogs. Cancer Treatment Rev 17:133-138, 1990
6. Ripamonti M, Pezzoni G, Pesenti E, Pastori A, Farao M, Bargiotti A, Suarato A, Spreafico F, Grandi M: In vivo anti-tumor activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin-resistant tumour cells. Br J Cancer 65:703-707, 1992
7. Coley HM, Twentyman PR, Workman P: 9-alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. Eur J Cancer 26:665-667, 1990
8. Mariani M, Capolongo L, Suarato A, Bargiotti A, Mongelli N, Grandi M, Beck WT: Growth-inhibitory properties of novel anthracyclines in human leukemic cell lines expressing either Pgp-MDR or at-MDR. Invest New Drugs 12:93-97, 1994
9. Geroni C, Pesenti E, Broggini M, Belvedere G, Tagliabue G, D'Incalci M, Pennella G, Grandi M: L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives. Br J Cancer 69:315-319, 1994
10. Facchetti I, Grandi M, Cucchi P, Geroni C, Penco S, Vigevani A: Influence of lipophilicity on cytotoxicity of anthracyclines in LoVo and LoVo/DX human cell lines. Anti-Cancer Drug Design 6:385-397, 1991
11. Graham MA, Clugson CK, King LH, Riley RI, Morrison JC, Cummings I, Kerr DJ, Workman P: Mechanistic studies with methoxymorpholino-doxorubicin: evidence of a novel covalently bound DNA adduct following activation by CYT P450 3A. Proc AACR:abstract 3065, 1992
12. Duran GE, Lewis AD, Lau DHM, Bammler TK, Sikic BI: Differential single versus double-strand DNA breakage produced by doxorubicin and its morpholino derivatives. Proc AACR:abstract 1975, 1991
13. Lau DHM, Lewis AD, Sikic BI: Association of DNA cross linking with potentiation of the morpholino-derivative of doxorubicin by human liver microsomes. J Natl Cancer Inst 81:1034, 1989
14. Lau DHM, Duran GE, Lewis AD, Sikic BI: Metabolic conversion of methoxymorpholinyl doxorubicin: from DNA strand breaker to a DNA cross-linker. Br J Cancer 90:79-84, 1994
15. Drewinko B, Romsdahl MM, Yang LY, Ahearn MJ, Trajillo JM: Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Res 36:467-475, 1990
16. Grandi M, Geroni C, Giuliani FC: Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicin. Br J Cancer 54:515-518, 1986
17. Dawe CJ, Potter M: Scientific proceedings. Amer J Path 33:603, 1957
18. Johnson RK, Chitnis MP, Embrey WM, Gregory EB: In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep 62:1535, 1978
19. Suarato A, Angelucci F, Bargiotti A, Caruso M, Faiardi D, Capolongo L, Geroni C, Ripamonti M, Grandi M: Synthesis and study of structure-activity relationships of new anthracyclines. In: Priebe W (ed) Anthracycline Antibiotics - New Analogues, Methods of Delivery, and Mechanisms of Action. American Chemical Society, Washington, 1995, pp 142-145
20. Geroni MC, Pennella G, Ripamonti M, Bargiotti A, Suarato A, Grandi M: The (2′R) and (2′S) enantiomers of methoxymorpholinyldoxorubicin present equivalent antitumor activity and select two different modes of resistance. Proc AACR:abstract 2415, 1994
21. Ripamonti M, Geroni MC, Pastori A, Suarato A, Bargiotti A, Todeschi S, D'Incalci M, Trizio D, Grandi M: FCE 27726, a novel alkylating anthracycline: lack of cross resistance to known antitumor drugs and pattern of antitumor activity. Proc AACR:abstract 2416, 1994